恒瑞医药宣布重磅减肥创新药 Ⅲ 期临床试验获得积极顶线结果

制药网
22 Jul

【制药网 企业新闻】近日,恒瑞医药宣布了一则振奋人心的消息:GLP-1/GIP 双重受体激动剂 HRS9531 注射液治疗中国肥胖或超重受试者的 Ⅲ 期临床试验(HRS9531-301)获得积极顶线结果。这一成果不仅为恒瑞医药在代谢性疾病治疗药物研发领域增添了浓墨重彩的一笔,更为广大肥胖及超重患者带来了新的希望。​恒瑞医药作为国内创新药研发的企业,多年来持续投入大量资源进行创新药物的研究与开发,在...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10